• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • HIV/AIDS
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • HIV/AIDS
    • View Item
    Mar 04, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Musinguzi, N
    Mocello, RA
    Boum, Y
    Hunt, PW
    Martin, JN
    Haberer, JE
    Bangsberg, DR
    Siedner, MJ
    Issue Date
    2016-06-02
    Submitted date
    2016-06-15
    
    Metadata
    Show full item record
    Journal
    AIDS and Behavior
    Abstract
    Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia.
    Publisher
    SpringerLink We regret that this article is behind a paywall.
    URI
    http://hdl.handle.net/10144/618825
    DOI
    10.1007/s10461-016-1447-1
    PubMed ID
    27256394
    Language
    en
    ISSN
    1573-3254
    ae974a485f413a2113503eed53cd6c53
    10.1007/s10461-016-1447-1
    Scopus Count
    Collections
    HIV/AIDS

    entitlement

    Related articles

    • Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    • Authors: Haberer JE, Musinguzi N, Boum Y 2nd, Siedner MJ, Mocello AR, Hunt PW, Martin JN, Bangsberg DR
    • Issue date: 2015 Dec 1
    • Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.
    • Authors: Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS
    • Issue date: 2010 Dec
    • Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
    • Authors: Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, Baeten JM
    • Issue date: 2016 Feb
    • Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
    • Authors: Benning L, Mantsios A, Kerrigan D, Coleman JS, Golub E, Blackstock O, Konkle-Parker D, Philbin M, Sheth A, Adimora AA, Cohen MH, Seidman D, Milam J, Kassaye SG, Taylor T, Murray M
    • Issue date: 2020 Jul 25
    • A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    • Authors: O'Connor JL, Gardner EM, Esser S, Mannheimer SB, Lifson AR, Telzak EE, Phillips AN, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
    • Issue date: 2016 Feb
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.